Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
976 stopped studies mapped to Digestive System Carcinoma and descendants · 93% state a reason
Over the 976 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03867370 | Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable… | Phase 1 / Phase 2 | terminated | Mar 8, 2019 | Shanghai Junshi Bioscience Co., Ltd. | Enrollment is over, the study was completed | Enrollment / accrual |
| NCT05641922 | Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of…(PANORAMA2) | N/A | withdrawn | Dec 8, 2022 | Techsomed Medical Technologies LTD | Withdrawn by Sponsor | Other (stated, no rule matched) |
| NCT01690715 | Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in…(HSL2012-06) | — | terminated | Sep 24, 2012 | Hospital Sirio-Libanes | There was recruted subject | Other (stated, no rule matched) |
| NCT04329949 | Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic…(RELIANT) | Phase 3 | terminated | Apr 1, 2020 | Corcept Therapeutics | The independent data monitoring committee found no safety issues, however the observed response… | Safety / toxicity |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine… | Phase 1 | withdrawn | Oct 26, 2020 | QuantumLeap Healthcare Collaborative | Study withdrawn as scientific interest in pursuing the SYD985+Paclitaxel combination has diminished. | Other (stated, no rule matched) |
| NCT04066491 | Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With… | Phase 2 / Phase 3 | terminated | Aug 26, 2019 | EMD Serono Research & Development Institute, Inc. | Based on a review of data conducted by the Independent Data Monitoring Committee (IDMC), Sponsor… | Sponsor / business decision |
| NCT04565327 | Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal… | Phase 2 | terminated | Sep 25, 2020 | Zhen Wang, MD | Slow accrual | Enrollment / accrual |
| NCT05111314 | Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for… | Early Phase 1 | withdrawn | Nov 8, 2021 | Mayo Clinic | PI requested | Other (stated, no rule matched) |
| NCT04054752 | Vaccine Response With NT-I7 | Phase 1 | withdrawn | Aug 13, 2019 | National Cancer Institute (NCI) | No subjects enrolled. | Enrollment / accrual |
| NCT04983407 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced… | Phase 1 / Phase 2 | terminated | Jul 30, 2021 | Aravive, Inc. | Due to business reasons | Sponsor / business decision |
| NCT01545141 | Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer | Phase 1 / Phase 2 | terminated | Mar 6, 2012 | Roswell Park Cancer Institute | not stated | Not stated |
| NCT01307956 | Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or… | Phase 2 | terminated | Mar 3, 2011 | University of Nebraska | Drug manufacturer - Amgen requested study stop, per DSMB observation in POWER trial | Drug supply |
| NCT04235660 | Y90 Radiation Segmentectomy vs SBRT for HCC(SBRT vs Y90) | N/A | terminated | Jan 22, 2020 | Indiana University | unable to recruit. terminated due to futility | Efficacy / futility |
| NCT02383433 | Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer | Phase 2 | terminated | Mar 9, 2015 | Case Comprehensive Cancer Center | PI discretion based on low accrual | Enrollment / accrual |
| NCT04977401 | EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection(EPSILON) | N/A | terminated | Jul 26, 2021 | Erasme University Hospital | Urgent Medical Device Product (ORISE Gel Submucosal Liftiong Agent) Removal by sponsor | Other (stated, no rule matched) |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With… | Phase 1 / Phase 2 | withdrawn | Oct 19, 2023 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03592641 | Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal… | Phase 2 | terminated | Jul 19, 2018 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT03722108 | Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic…(REGIRI) | Phase 1 / Phase 2 | terminated | Oct 26, 2018 | UNICANCER | Unfavorable benefit-risk balance in the experimental arm following the IDMC for intermediate… | Safety / toxicity |
| NCT03490760 | Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas | Phase 2 | terminated | Apr 6, 2018 | Baptist Health South Florida | Slow/poor enrollment | Enrollment / accrual |
| NCT02847468 | Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission…(PREMETHEP) | N/A | terminated | Jul 28, 2016 | Centre Georges Francois Leclerc | Insufficient recruitment | Enrollment / accrual |
| NCT03122106 | Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and… | Phase 1 | terminated | Apr 20, 2017 | Washington University School of Medicine | Loss of funding | Funding |
| NCT04428437 | Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line… | — | terminated | Jun 11, 2020 | Humanity & Health Medical Group Limited | The sponsor withdrawed the sponsorship to the study. | Other (stated, no rule matched) |
| NCT00745134 | Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating… | Phase 2 | terminated | Sep 3, 2008 | M.D. Anderson Cancer Center | The trial was stopped early because there was only one patient with pCR among the first 15 patients… | Other (stated, no rule matched) |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT05435053 | Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer(CHECKPOINT) | Phase 2 | terminated | Jun 28, 2022 | Ismail Gögenur | The study was terminated on the basis on an evaluation of the safety and efficacy of the 9 included… | Safety / toxicity |
| NCT04099888 | PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With…(RELEASE) | Phase 2 | terminated | Sep 23, 2019 | PCI Biotech AS | Recent results from a Phase 3 study are expected to change the standard of care for patients with… | Other (stated, no rule matched) |
| NCT04566133 | Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy… | Phase 2 | terminated | Sep 28, 2020 | National Cancer Institute (NCI) | Slow accrual | Enrollment / accrual |
| NCT05510427 | Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The… | Phase 1 | withdrawn | Aug 22, 2022 | M.D. Anderson Cancer Center | Per PI's request | Other (stated, no rule matched) |
| NCT04066894 | Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal… | Phase 2 | terminated | Aug 26, 2019 | M.D. Anderson Cancer Center | Due to Issues Enrolling Patients | Enrollment / accrual |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in…(ALpha-T) | Phase 2 | terminated | Nov 25, 2020 | Hoffmann-La Roche | The data from this study is no longer needed. | Other (stated, no rule matched) |
| NCT05109052 | Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating… | Phase 1 / Phase 2 | withdrawn | Nov 5, 2021 | University of Rochester | no accrual of eligible participants | Enrollment / accrual |
| NCT03970616 | A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced…(DEDUCTIVE) | Phase 1 / Phase 2 | terminated | May 31, 2019 | AVEO Pharmaceuticals, Inc. | The study was terminated due to regulatory approval of newer therapeutic options and slower than… | Enrollment / accrual |
| NCT03722498 | Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE | Phase 2 | withdrawn | Oct 29, 2018 | Sun Yat-sen University | No patients join | Other (stated, no rule matched) |
| NCT02530437 | Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With… | Phase 1 / Phase 2 | terminated | Aug 21, 2015 | M.D. Anderson Cancer Center | The sponsor sold the drug TALADEGIB to another company during the trial and thereafter no drug was… | Sponsor / business decision |
| NCT03591965 | Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular… | Phase 2 | terminated | Jul 19, 2018 | Antengene Therapeutics Limited | Based on the adjustment of clinical research and development strategy，sponsor decided to terminate… | Sponsor / business decision |
| NCT00303628 | Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III… | Phase 3 | terminated | Mar 17, 2006 | ECOG-ACRIN Cancer Research Group | The study was terminated before reaching its accrual goal due to slow accrual. | Enrollment / accrual |
| NCT02150967 | A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma | Phase 2 | terminated | May 30, 2014 | QED Therapeutics, a BridgeBio company | The study was terminated early due to limited efficacy in Cohorts 2 and 3 (exploratory endpoints).… | Safety / toxicity |
| NCT05216120 | Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas | Phase 2 | withdrawn | Jan 31, 2022 | HonorHealth Research Institute | enrollment challenges | Enrollment / accrual |
| NCT02031536 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver… | Phase 2 | terminated | Jan 9, 2014 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT02515513 | The Role of Muscle Cachexia in Pancreatic Cancer | N/A | withdrawn | Aug 4, 2015 | University of Florida | Original PI left the institution. No subjects enrolled | Investigator |
| NCT00301379 | Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients | — | terminated | Mar 10, 2006 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT04348916 | Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With… | Phase 1 | terminated | Apr 16, 2020 | Oncorus, Inc. | Terminated due to Oncorus portfolio reprioritization | Sponsor / business decision |
| NCT05564338 | Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus… | Phase 3 | withdrawn | Oct 3, 2022 | BeiGene | Study has voluntarily discontinued due to a change in the company-level development strategy and is… | Safety / toxicity |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch…(REFIT-MSS) | Phase 2 | withdrawn | Oct 17, 2022 | Translational Research in Oncology | Study never started/ will not proceed. | Other (stated, no rule matched) |
| NCT05886257 | Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T | Phase 2 | withdrawn | Jun 2, 2023 | Shi Ming | Protocol adjustment | Other (stated, no rule matched) |
| NCT05375604 | A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma… | Phase 1 | terminated | May 16, 2022 | Codiak BioSciences | Company Bankruptcy | Sponsor / business decision |
| NCT03233724 | Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated… | Phase 1 / Phase 2 | terminated | Jul 31, 2017 | National Cancer Institute (NCI) | Study terminated due to drug supply issues. | Drug supply |
| NCT02344810 | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating… | Phase 1 / Phase 2 | withdrawn | Jan 26, 2015 | Eastern Cooperative Oncology Group | The study did not open to accrual. No start date and no completion dates. | Enrollment / accrual |
| NCT05039736 | A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR… | Phase 2 | withdrawn | Sep 10, 2021 | M.D. Anderson Cancer Center | 0 participants accrued | Enrollment / accrual |
| NCT02174575 | Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery | Phase 4 | withdrawn | Jun 25, 2014 | Tokyo Medical and Dental University | I retired my post before enrollment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Nov 29, 2023source: clinicaltrials